News

News2025-07-02T17:16:16-04:00

HMS in the News

Recent Releases

2402, 2022

Breakthrough Cures, Blockbuster Costs: Future Directions

February 24, 2022|

Health, Medicine & Society

Published by Blue Cross Blue Shield Association and HMS, this report examines advanced therapies—biomedical breakthroughs that often treat rare conditions and can transform or even save a patient’s life—that tend to come with extremely high price tags. By 2031, as many as 90 gene and cellular therapies are expected to be approved for use by 550,000 patients, at an annual acquisition cost of $30 billion. A framework for ensuring that high-cost medicines for rare conditions are affordable and accessible to patients emerged from a convening co-chaired by two former U.S. Food and Drug Administration (FDA) commissioners, Scott Gottlieb and Margaret Hamburg.

Go to Top